Navigation Links
Genoa Pharmaceuticals announces $1.2M Financing
Date:11/8/2012

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Genoa Pharmaceuticals, a biotechnology company developing novel therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF), announced today the completion of a $1.2M financing. Funds from the financing will be used to advance its lead program, GP-101 (aerosol pirfenidone). IPF is a fatal lung disease caused by both genetic and environmental factors resulting in progressive lung scarring and characterized by reduced exercise capacity and chronic cough. IPF affects approximately 200,000 Americans and 135,000 Europeans.

Genoa was founded by Mark Surber, Ph.D., an aerosol development expert formerly with Mpex and Aires Pharmaceuticals. Dr. Surber serves as Genoa's President and Chief Scientific Officer. "IPF is a very serious disease with only 20% of patients surviving five years," said Dr. Surber. "Currently, there are no U.S. approved drugs, leaving lung transplant as the only option to extend life. Genoa's approach could be a significant advancement to treat patients with this devastating disease and we are excited about the opportunity to progress GP-101 into development."

Outside the United States, only oral pirfenidone is approved for the treatment of IPF. Sold by InterMune in Europe and Shionogi in Japan, this product has shown promise to extend life. However, the oral drug has been associated with gastrointestinal side effects that limit dosing and challenge patient compliance. To address this unmet need, Genoa has created GP-101 as a proprietary aerosol pirfenidone formulation for direct inhalation delivery to the lung. Compared to the oral medicine, inhaled GP-101 delivers an increased pirfenidone lung dose with improved pharmacokinetic parameters. As inhalation delivers more pirfenidone directly to the lung with reduced gastrointestinal exposure, inhaled GP-101 has the potential to improve the efficacy and safety profile of pirfenidone.

"We are pleased to have raised this initial seed financing," said Michael J. Kamdar, Genoa's Co-Founder and Chief Business Officer. "This financing will allow us to advance GP-101 to a key inflection point for prospective partners and investors by early 2013."

About Genoa Pharmaceuticals

Genoa Pharmaceuticals is committed to developing improved therapies for the treatment of Idiopathic Pulmonary Fibrosis. Based in San Diego, Genoa's lead program GP-101 (aerosol pirfenidone) is advancing towards the clinic for the treatment of IPF. Learn more at www.genoapharma.com


'/>"/>
SOURCE Genoa Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
2. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
3. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
4. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
5. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
6. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
7. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
8. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
10. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
11. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):